Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Lebrikizumab and Mometasone Furoate for Adults with Perennial Allergic Rhinitis

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Perennial Allergic Rhinitis, a condition where individuals experience year-round allergy symptoms such as a runny nose, nasal congestion, itching, and sneezing. The study will evaluate the effectiveness and safety of a medication called Lebrikizumab, which is given as a solution for injection. Participants in the study will receive either Lebrikizumab or a placebo, which is a substance with no active medication.

The purpose of the study is to assess how well Lebrikizumab can reduce the total nasal symptoms in adults with perennial allergic rhinitis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will attend regular visits to monitor their symptoms and overall health. The main focus will be on changes in the severity of nasal symptoms from the start of the study to the end of the 16-week period. The study aims to provide valuable information on the potential benefits of Lebrikizumab for individuals suffering from perennial allergic rhinitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant is confirmed to have a physician-diagnosed condition known as perennial allergic rhinitis.

    Eligibility is further confirmed through a positive skin prick test with indoor allergens or a positive antigen-specific serum immunoglobulin E (IgE) test.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish a baseline for the total nasal symptom score (TNSS).

    The TNSS is a composite score of four symptoms: rhinorrhea (runny nose), nasal congestion, nasal itching, and sneezing. Each symptom is scored from 0 (none) to 3 (severe), with a total score range of 0 to 12.

  3. Step 3

    Treatment phase

    Participants are randomly assigned to receive either lebrikizumab or a placebo.

    Lebrikizumab is administered as a subcutaneous injection.

    The treatment phase lasts up to 16 weeks, during which the efficacy of lebrikizumab is evaluated.

  4. Step 4

    Nasal spray administration

    Participants may also use a nasal spray containing mometasone furoate as part of their treatment regimen.

    The nasal spray is used to help manage symptoms of perennial allergic rhinitis.

  5. Step 5

    Evaluation of treatment efficacy

    The primary objective is to evaluate the change in the total nasal symptom score from baseline to week 16.

    The effectiveness of lebrikizumab is compared to the placebo based on the reduction in symptom severity.

  6. Step 6

    Completion of the study

    The study is estimated to conclude by August 3, 2026.

    Participants' progress and any changes in symptoms are documented throughout the study duration.

Who can join the trial?

7 criteria

  • The patient must have been diagnosed by a doctor with Perennial Allergic Rhinitis (PAR), which is a type of allergy that occurs all year round.
  • The patient must have a positive result on a skin prick test (SPT) for indoor allergens. This test checks for allergic reactions by placing a small amount of allergen on the skin and pricking it.
  • The patient can also have a positive result on a blood test for immunoglobulin E (IgE), which is a type of antibody that the body makes in response to allergens. The level must be 0.70 kU/L or higher.
  • If the patient has dermatographism, which is a condition where the skin becomes raised and inflamed when scratched, they can still participate if they have a positive IgE blood test.
  • If the patient has asthma, it must be stable for at least 3 months before the study starts, and they must be using regular asthma treatment that is allowed in the study.
  • The study is open to both male and female patients.
  • The study includes patients who are considered part of a vulnerable population, which means they might need extra protection or care.

Who cannot join the trial?

9 criteria

  • Having a different condition than Perennial Allergic Rhinitis (PAR), which is a type of allergy that happens all year round.
  • Being outside the age range specified for the study.
  • Having any health issues that the study doctors think might make it unsafe to participate.
  • Being pregnant or planning to become pregnant during the study period.
  • Currently participating in another clinical trial.
  • Having a history of severe allergic reactions to medications.
  • Using certain medications that might interfere with the study treatment.
  • Having a history of drug or alcohol abuse.
  • Having any other medical condition that the study doctors think might affect the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lebrikizumab: This medication is being studied for its effectiveness in treating perennial allergic rhinitis, which is a type of allergy that causes symptoms like a runny or stuffy nose throughout the year. The trial aims to see how well lebrikizumab can reduce these nasal symptoms over a period of 16 weeks.

What is already known about the treatment

Lebrikizumab – This medication is administered as an injection and is currently being studied in clinical trials for its effectiveness in treating Perennial Allergic Rhinitis (PAR). It is in the phase 3 stage of clinical trials, which means it is being tested for safety and efficacy in a larger group of participants. The main therapeutic use of Lebrikizumab is to alleviate symptoms associated with chronic allergic reactions, such as nasal congestion and sneezing. At the molecular level, Lebrikizumab works by targeting and inhibiting a specific protein involved in the inflammatory response, thereby reducing allergy symptoms. It is classified as a monoclonal antibody, which is a type of medication designed to interact with specific targets in the immune system.

Investigated diseases

Perennial Allergic Rhinitis – This is a condition characterized by inflammation of the nasal passages due to allergens present throughout the year, such as dust mites, pet dander, or mold. Symptoms include a runny nose, nasal congestion, sneezing, and itching, which can persist continuously or intermittently. The condition is triggered by an immune response to allergens, leading to the release of histamines and other chemicals that cause inflammation. Over time, the persistent symptoms can affect daily activities and quality of life. The severity of symptoms can vary, with some individuals experiencing mild discomfort and others facing more significant challenges.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-508817-18-00Protocol codeJ2T-MC-KGBTEstimated enrolment518 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.